DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
▼ + stars: | 2024-03-08 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Liselotte Sabroe | AFP | Getty ImagesWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value, after fresh early trial data showed positive results for its new experimental weight loss pill. Novo Nordisk is now the 12th most valuable company in the world, with a market cap of $604 billion — ahead of Tesla's $569 billion, according to FactSet data. 8The uptick of Thursday extends a months-long rally for Novo Nordisk, as excitement grows around weight loss drugs and their potential wider applications. The early amycretin data marks a fresh milestone for Novo Nordisk, potentially offering a more effective and less intrusive alternative to its already widely successful injection-based Wegovy and Ozempic drugs. Wegovy showed weight loss of 6% in a 12-week trial, while Ozempic is a diabetes treatment.

Persons: Liselotte Sabroe, Eli Lilly, amycretin, Martin Holst Lange, Lange Organizations: AFP, Getty, Novo Nordisk, Tesla, Microsoft Corp MSFT, Apple Inc, AAPL, NVIDIA Corp NVDA Technology, Saudi Aramco, SA Energy, Inc, AMZN Consumer, GOOGL, Berkshire Hathaway BRK.B, Company LLY Healthcare, Broadcom Inc, AVGO Technology, Taiwan Semiconductor TSM, Novo Nordisk NVO, Finance, JPMorgan Chase JPM, Reuters Locations: Bagsvaerd, Copenhagen, Denmark, Danish, London, Saudi, Mar, Europe

☆ Cigna will cap how much insurance can spend on weight loss drugs as it tries to expand coverage
▼ + stars: | 2024-03-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Cigna on Thursday said it will limit how much health plans and employers spend on weight loss drugs each year in a bid to expand insurance coverage for those highly popular treatments. The effort by insurance giant Cigna could make weight loss treatments more accessible. They deferred CNBC to Cigna for details on the insurance spending cap. Those medicines treat weight loss and diabetes by mimicking one or more hormones produced in the gut to suppress appetite and regulate blood sugar. Cigna said providing "financial predictability" through a cost cap will allow health plans and employers to better plan to manage GLP-1 spending.

Persons: Cigna, Eli Lilly Organizations: CNBC, drugmakers Novo Nordisk, Novo Nordisk Locations: Oslo, Norway, mull

☆ Chip stocks soar — plus, this lagging industrial is due for a catch-up trade
▼ + stars: | 2024-03-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. In fact, about half of the S & P 500's industrial stocks have hit records high since the start of 2024. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Powell, Jerome Powell, Jim, Shrugging, Eli Lilly, It's, Lilly, Cramer, Linde, TJ Maxx, we'll, Jim Cramer's, Alwyn Scott Organizations: CNBC, Federal, Qualcomm, Broadcom, Nvidia, Arm Holdings, Devices, Novo Nordisk, Club, Palo Alto, Palo, Honeywell, Aerospace, Berenberg, Eaton Corp, Burlington Stores, Marshalls, TJX Companies, Costco, Marvell Technology, Inc, Bloomberg, Jim Cramer's Charitable, Honeywell Aerospace Locations: cybersecurity, America, Phoenix

☆ Stocks making the biggest moves midday: Victoria's Secret, Novo Nordisk, Intel, Shake Shack and more
▼ + stars: | 2024-03-07 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Victoria's Secret said it anticipates a larger-than-expected decline in revenues for the first quarter and full year. Novo Nordisk — Shares rallied nearly 8.9% to record high level after the company reported positive Phase I trial results for its new experimental weight loss drug amycretin. The company reported adjusted earnings of 61 cents per share on $1.68 billion in revenue for its fiscal fourth quarter. Analysts had estimated earnings of 50 cents per share on $1.67 billion in revenue, according to LSEG. Burlington Stores — The stock rose 7.5% after Burlington posted a fourth-quarter beat on adjusted earnings per share and revenue.

Persons: Victoria's, amycretin, TD Cowen, Shake Shack's, Kroger, LSEG, Iberdrola, Avangrid's, Mizuho, —, Samantha Subin Organizations: Novo Nordisk —, American Eagle Outfitters, Burlington Stores, Burlington, New York Community Bancorp, Liberty Strategic, VanEck Semiconductor, Nvidia, Micron Technology, Stifel, Intel, Bloomberg Locations: Spanish

☆ Stocks making the biggest moves premarket: Novo Nordisk, New York Community Bancorp, Victoria's Secret, Nvidia and more
▼ + stars: | 2024-03-07 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Nvidia — Semiconductor companies rose broadly as a group, with the VanEck Semiconductor ETF gaining 1.5% in the premarket. Intel shares rose 1.7%. Kroger — Shares rose 6% after the supermarket chain reported fourth-quarter better-than-expected earnings. Analysts expected a profit of 50 cents per share on revenue of $1.67 billion, according to LSEG. Victoria's Secret expects $6 billion full-year revenue, less than the $6.2 billion expected from analysts polled by FactSet.

Persons: Eli Lilly, Mizuho, LSEG, Tesla, NYCB, — CNBC's Michelle Fox, Hakyung Kim, Jesse Pound, Pia Singh Organizations: Nordisk —, Nvidia — Semiconductor, VanEck Semiconductor, Nvidia, Micron Technology, Stifel, Broadcom, Intel, Kroger, Eagle Outfitters, Citi, York Community Bancorp, FactSet, York Community Locations: Danish, American

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Apple, Microsoft, Oracle, Arm, Rivian, Lyft & more
▼ + stars: | 2024-03-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: Goldman Sachs reiterates Tesla and Rivian as neutral Goldman said further price cuts are needed for Tesla and Rivian. Morgan Stanley downgrades Sunnova to equal weight from overweight Morgan Stanley said in its downgrade of the solar company that it sees stock "dislocation." JPMorgan upgrades Sea Limited to overweight from neutral JPMorgan said the Singapore-based internet tech conglomerate is on an "upswing." JPMorgan initiates Amphastar as overweight JPMorgan said it's bullish on shares of the pharmaceutical company. JPMorgan initiates Metagenomi as overweight JPMorgan said it's bullish on shares of the biotech company.

Persons: Goldman Sachs, Tesla, Goldman, TD Cowen, Arm's, Ian Thornton, Morgan Stanley downgrades Sunnova, Morgan Stanley, Baird, DA Davidson, it's, Jefferies, BJ's, it's bullish, Oppenheimer, Wolfe, Rosenblatt, Moffett, Philip Morris, Guggenheim Organizations: Tesla, Nvidia, NVIDIA, Microsoft, JPMorgan, Jefferies, UBS, disinflation, Barclays, Oracle, Citi, Novo Nordisk, CMD, Costco, Adobe, Williams, Apple, Cable, . Cable, Argus, Guggenheim, Lyft Locations: Singapore, China, Sonoma

☆ Novo Nordisk Ozempic cuts risk of kidney disease progression
▼ + stars: | 2024-03-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novo Nordisk 's blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday. Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compared to a placebo. Chronic kidney disease would be a big additional treatment opportunity for Ozempic: Roughly 40% of people with diabetes also have the condition. The trial, called FLOW, first started in 2019 and followed roughly 3,500 patients with diabetes and moderate to severe chronic kidney disease. Last year, a late-stage trial on Wegovy showed that it cut the risk of heart attacks and strokes by 20%.

Persons: Ozempic, –, Eli Lilly Organizations: Novo Nordisk, U.S Locations: Riedisheim, France, Europe, Danish, Novo

☆ Cramer says get ready to buy if there's a market sell-off: 'I have my shopping list'
▼ + stars: | 2024-03-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday disputed talk of sector bubbles, saying investors should be prepared to buy if there's a sell-off and undervalued stocks pull back. "I will be ready to buy if this market sells off," he said. He opined about the burgeoning artificial intelligence sector, saying that despite its current popularity, investors may not yet conceive of how influential this new technology will be. Cramer also pointed to Nvidia — which recently closed above the $2 trillion market cap — and said the company hasn't been overvalued. "I'm not fretting, I'm just expecting, and I have my shopping list of what to buy on weakness for the charitable trust."

Persons: CNBC's Jim Cramer, Cramer, hasn't, Wall, Nvidia's, —, Eli Lilly, I'm Organizations: Nvidia, Novo Nordisk

☆ Veteran investor picks 'Glorious 10' global stocks with 30% annual gains over the last 5 years
▼ + stars: | 2024-03-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

However, veteran investor and trader Adam Reynolds says it's time to look beyond the U.S. and consider 10 lesser-known companies from across Europe, Japan and Australia. "The focus on U.S. tech stocks — and especially the Magnificent Seven — is driving huge amounts of performance to the U.S. stock market. Calling valuations of U.S. stocks "stretched," Reynolds said there are opportunities in moving toward a "more diversified global portfolio," including better valuations — and returns. In terms of allocation, Reynolds suggests that investors put 30% of their equities portfolio in U.S. stocks, 40% in Asia and 30% in Europe. Chip stocks Shares of semiconductor manufacturer Tokyo Electron are up over 140% over the last 12 months.

Persons: Adam Reynolds, Reynolds, we're, Reynold Organizations: Big Tech, Apple, Microsoft, Nvidia, Tesla, Saxo Capital Markets, CNBC Pro, Japan, Tokyo, Novo Nordisk, Nordisk, BYD, Ferrari Locations: Europe, Japan, Australia, Asia, Tokyo, Europe's

Even as countries around the world have stepped in to require lower priced drugs for their citizens, the United States has been reticent to do so. As a result, U.S. consumers pay the highest prices in the world for drugs, by a wide margin. But the impetus for more fundamental reform may come from an unexpected place: America’s obesity epidemic. Many of us are aware that there is a new class of weight-loss drugs that offer enormous promise in addressing obesity. But there is far less awareness of the fact that these drugs also introduce an enormous risk to America’s taxpayers.

Organizations: pharma, Novo Nordisk, Ozempic Locations: United States, U.S, Danish

☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
▼ + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.

Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey

☆ Citi names 'Super 7' global stocks similar to the Magnificent 7 — but cheaper
▼ + stars: | 2024-03-01 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Citi has identified European stocks it says are similar to the high-flying " Magnificent Seven " U.S. technology stocks, but trade at cheaper valuations leaving more room for them to rise. Citi's resulting Super Seven picks are Novo Nordisk , ASML , LVMH , SAP , Schneider Electric , Richemont and Ferrari . All of the stocks stocks also trade in the United States. Despite the rally over the past year, Citi points out that as a group, the Super Seven have lagged the Magnificent Seven, with 70% less appreciation since early 2023, leaving more upside potential. Looking ahead, Citi said the Super Seven was well positioned to continue outperforming should current "narrow" market conditions persist, and cautioned against selling stocks on the basis of a narrow market leadership.

Persons: Beata M, — CNBC's Charlotte Reed Organizations: Citi, Nvidia, Apple, Microsoft, Meta, Novo Nordisk, ASML, SAP, Schneider, Ferrari Locations: Europe, LVMH, United States

☆ Europe is having its worst earnings season since the onset of Covid — with little hope of a quick turnaround
▼ + stars: | 2024-03-01 | by ( Silvia Amaro | ) www.cnbc.com time to read: +4 min

As of Feb. 29 with 313 companies having reported, 50.2% posted a beat, according to a CNBC analysis of FactSet data. This was the smallest percentage of beats — thus the worst earnings season — since the first quarter of 2020 when the pandemic first hit European firms. Share buyback bonanzaSharon Bell, a senior European strategist at Goldman Sachs, told CNBC that she had noticed a new trend for European corporates during this earnings season. "What you have seen is a lot of companies announcing buybacks," she told CNBC's "Squawk Box Europe" Tuesday. "It is absolutely huge, you've never really seen this before in 20, 30 years, European companies pay dividends, they don't do buybacks," she said.

Persons: —, Edward Stanford, Philippe Ferreira, Kepler Cheuvreux, Sharon Bell, Goldman Sachs, CNBC's, you've, Bell, Ferreira Organizations: CNBC, HSBC, L'Oreal, European Central Bank, Shell, Deutsche Bank, Novo Nordisk, UBS Locations: Triomphe, France, Europe, China, Ukraine, European

☆ European markets set for gains ahead of euro zone inflation data
▼ + stars: | 2024-03-01 | by ( Elliot Smith | ) www.cnbc.com time to read: +1 min

A TV presenter gets ready for the daily reporting from the floor of the German share price index DAX at the stock exchange in Frankfurt, Germany, November 15, 2023. LONDON — European markets are set to open higher on Friday to start the new trading month after a winning February, with euro zone inflation data due mid-morning. The European stock index notched an all-time high last month, powered by the 11 GRANOLAS large-cap stocks that made up half of the gains across the entire Stoxx 600. Focus will turn Friday to February's flash euro zone inflation reading, expected at 10 a.m. London time, with economists in a Reuters poll predicting the consumer price index rose 2.5% year on year, down from 2.8% in January. German consumer price inflation on Thursday came in line with forecasts at 2.7% year on year.

Persons: DAX Organizations: LONDON, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Focus, European Central Bank, ECB, Fed Locations: Frankfurt, Germany, London

☆ Judge rejects AstraZeneca’s challenge to Medicare drug price negotiations
▼ + stars: | 2024-03-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge on Friday rejected AstraZeneca 's legal challenge to Medicare's new power to negotiate the prices of certain costly prescription drugs with manufacturers. The decision is another win for the Biden administration in a bitter legal fight with the pharmaceutical industry over the constitutionality of those price talks. The opportunity to sell drugs to more than 49 million Medicare and Medicaid beneficiaries is a "powerful incentive" for manufacturers to participate in the price talks with the government, Connolly wrote. The ruling comes a month after a federal judge in Texas tossed a separate lawsuit challenging the price talks. On March 7, Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson will present their oral arguments to a federal judge in New Jersey in the same hearing.

Persons: AstraZeneca, Biden, AstraZeneca's, Colm Connolly, Connolly, Johnson Organizations: U.S . Department of Health, Human Services, Washington , D.C, Manufacturers, Supreme, District, AstraZeneca, Chamber of Commerce, Bristol Myers Squibb, Novo Nordisk, Novartis, Johnson, CNBC PRO Locations: Washington ,, Delaware, Texas, Ohio, New Jersey

☆ Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
▼ + stars: | 2024-02-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable

☆ CNBC Daily Open: Markets brace for Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

A trader works during the closing bell at the New York Stock Exchange (NYSE) on March 17, 2020 at Wall Street in New York City. This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Overnight, Wall Street ended lower as the 30-stock Dow slipped 0.06% and fell for a third consecutive session. Water scarcity threatens chip makersWater shortages could threaten semiconductor firms such as Taiwan Semiconductor Manufacturing Company, S&P Global Ratings said in a report.

Persons: Dow, Sundar Pichai, Pichai, Ziyu Shen, Eli Lilly, Freddie Lait, Lait Organizations: New York Stock Exchange, Wall, CNBC, CSI, Nikkei, Nasdaq, Google, Taiwan Semiconductor Manufacturing, Nvidia Geely, Nvidia, Novo Nordisk, McKesson Locations: New York City, Asia, U.S

☆ Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzCNBC’s Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.

Persons: Eli Lilly, Jared Holz, Melissa Lee Organizations: Novo Nordisk, Mizuho Securities Locations: Mizuho Securities America

☆ 'Exciting idea': Fund manager loves this pharma stock — and analysts see more upside ahead
▼ + stars: | 2024-02-29 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

But one firm in the wider ecosystem that's perhaps lesser known stands out to fund manager Freddie Lait, which is McKesson Corp — the U.S. pharmaceuticals distribution company. Calling the company an "exciting idea," Lait noted that the 100-year-old business is "very defensive and very diversified." Lait manages over $750 million collectively between two funds — the Latitude Horizon Fund and the Latitude Global Fund . Of the 19 analysts covering the stock, 14 give it a buy or overweight rating, while three have hold ratings and one has a sell rating. The average price target on the stock is $550.25, according to FactSet data, giving it potential upside of 6%.

Persons: Eli Lilly, Freddie Lait, Lait, —, That's, … It's, McKesson, MCK, — CNBC's Michael Bloom Organizations: Novo Nordisk, Latitude Investment Management, CNBC, U.S, Cardinal Health, McKesson Corp, JPMorgan, Rite Aid, receivables, Leerink Partners, pharma

☆ CNBC Daily Open: Wall Street on edge over Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Markets declineWall Street ended lower Wednesday as investors anxiously wait for the personal consumer expenditures reading for January due today. [PRO] A lesser-known pharma standoutInvestors have been piling into major weight-loss drug manufacturers like Eli Lilly and Novo Nordisk. But fund manager Freddie Lait picked a lesser-known firm that also stands out: McKesson Corp — the U.S. pharmaceuticals distribution company.

Persons: Jerome Powell, Dow, Sundar Pichai, Pichai, Tim Cook, Cook, Walt Disney, Mukesh Ambani, Eli Lilly, Freddie Lait, Lait Organizations: Federal Reserve, New York Stock Exchange, CNBC, Nasdaq, Google, Apple, Walt, Reliance, Asia's, JV, Novo Nordisk, McKesson Locations: New York City, U.S, India

☆ Jim Cramer says stay clear of this retail stock: 'It is not something you want to own'
▼ + stars: | 2024-02-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

First Solar : Shares rose more than 3% after the solar firm's quarterly earnings topped estimates, and its guidance was formidable. Urban Outfitters : Shares fell 13% after earnings, revenue and same-store sales growth missed Wall Street's expectations. While Cramer complimented the performance of its clothing-rental business, Nuuly, he said investors should not view Urban Outfitters as much more than an industry temperature check. That seems like good news for GE Healthcare , according to Cramer, whose Charitable Trust also owns shares of the medical-equipment maker. GE Healthcare has been the best-performing health-care stock in the S & P 500 in February, "and it's not done," Cramer said.

Persons: Jim Cramer's, Cramer, Eli Lilly Organizations: CNBC, Club, Novo Nordisk, Charitable Trust, Universal Health Services, GE Healthcare, Trust

☆ The pet drugs vets are now prescribing look a lot more like human medications
▼ + stars: | 2024-02-28 | by ( Ian Thomas | ) www.cnbc.com time to read: +7 min

If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don't need to look much further than weight loss drugs. When Pfizer spun off its animal health business in 2013 creating Zoetis, about 65% of the company's business was livestock-related. That has flipped now, with 64% of the company's revenue coming from products for companion animals like cats and dogs. Peck credits the Pfizer spinoff for allowing Zoetis to better balance what the company wanted to do in animal health versus the human health side. A similar product was approved for cats, marking the first time that monoclonal antibody treatments, which have become increasingly popular for treating human illnesses, have been used to treat pet osteoarthritis pain.

Persons: Kristin Peck, Eli Lilly, Peck, Zoetis, We've, it's, We'll Organizations: CNBC, Novo Nordisk, Pfizer, AstraZeneca, FDA

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ Cramer gives the portfolio's core holdings a makeover — 4 are booted, 6 are added including a trio of tech giants
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +12 min

COST 5Y mountain Costco's stock performance over the past five years. DHR 5Y mountain Danaher's stock performance over the past five years. ETN 5Y mountain Eaton Corp.'s stock performance over the past five years. "The megatrends are real serious, and [Eaton] is a real serious company," Jim said. TJX 5Y mountain TJX Companies' stock performance over the past five years.

Persons: Jim Cramer, Jeff Marks, Morgan Stanley, Wall, Beijing's, Jim, Eaton, Linde, Lilly's, Eli Lilly, We've, Zepbound, Mark Zuckerberg's, Mark Zuckerberg, OpenAI, Copilot, management's, Nvidia, TJ Maxx, TikTok, Gen Zers, TJX, Jim Cramer's, Satya Narayana Nadella, Lucas Jackson Organizations: GE Healthcare, Meta, Microsoft, Johnson, Natural Resources, Starbucks, Apple, Apple Music, Services, Amazon, Amazon Web Services, Prime, Costco, Danaher, Eaton Corp, Investors, GE, LIN, Novo Nordisk's Wegovy, Novo Nordisk, Management, Nvidia, TJX Companies, Marshalls, CNBC Locations: Eaton, China, Manhattan, New York City

Search resuls for: "nordisk"

25 mentions found